



RECEIVED


OCT 29 2001

TECH CENTER 1600/2900

USPTO Form 1449 (modified) Patent and Trademark Office INFORMATION DISCLOSURE CITATION	U.S. Department of Commerce	Attorney Docket No. 061765.00035 (3356/US)	Serial No. 09/912,233 #8
Page 1 of 9		Applicant(s): TREMONT et al.	
		Filing Date: July 25, 2001	Examiner: Unassigned Group: 16147 1624

U.S. PATENT DOCUMENTS

Examiner Initial	Doc Tab No.	Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)
BC	1	3,262,850	07/26/66	Glynne et al.	167	65	
BC	2	3,287,370	11/22/66	Mohrbacher et al.	260	327	
BC	3	3,389,144	06/18/68	Mohrbacher et al.	260	294.8	
BC	4	3,520,891	07/21/70	Mohrbacher	260	268	
BC	5	3,674,836	07/04/72	Creger	260	4736	
BC	6	3,692,895	09/19/72	Nelson et al.	424	78	
BC	7	3,714,190	01/30/73	Boissier et al.	260	327 TM	
BC	8	3,781,328	12/25/73	Witte et al.	260	471 R	
BC	9	3,948,973	04/06/76	Phillips	260	4736	
BC	10	3,962,261	06/08/76	Zinnes et al.	260	294.8	
BC	11	3,972,878	08/03/76	Schirmann et al.	260	2406	
BC	12	3,983,140	09/28/76	Endo et al.	260	343.5	
BC	13	4,002,750	01/11/77	Ambrogi et al.	424	250	
BC	14	4,058,552	11/15/77	Mieville	560	52	
BC	15	4,185,109	01/22/80	Rosen	424	275	
BC	16	4,231,938	11/04/80	Monaghan et al.	260	343.5	
BC	17	4,251,526	02/17/81	McCall	424	248.51	
BC	18	4,346,227	08/24/82	Terahara et al.	560	119	
BC	19	4,444,784	04/24/84	Hoffman et al.	424	279	
BC	20	4,559,332	12/17/85	Grob et al.	514	175	
BC	21	5,075,293	12/24/91	Reifschneider et al.	514	80	
BC	22	5,153,184	10/06/92	Reifschneider et al.	514	89	
BC	23	5,158,943	10/27/92	Sohda et al.	514	96	
BC	24	5,244,887	09/14/93	Straub	514	182	
BC	25	5,260,316	11/09/93	Van Duzer et al.	514	309	
BC	26	5,334,600	08/02/94	Van Duzer et al.	514	309	
BC	27	5,350,761	09/27/94	Van Duzer et al.	514	373	
BC	28	5,354,772	10/11/94	Kathawala	514	414	
BC	29	5,430,116	07/04/95	Kramer et al.	526	284	
BC	30	5,502,045	03/26/96	Miettinen et al.	514	182	
BC	31	5,512,558	04/30/96	Enhnen et al.	514	182	
BC	32	5,519,001	05/21/96	Bush et al.	514	12	
BC	33	5,602,152	02/11/97	Berthelon et al.	514	387	
BC	34	5,610,151	03/11/97	Glombik et al.	514	172	
BC	35	5,663,165	09/02/97	Brieady	514	211	
BC	36	5,703,188	12/30/97	Mandeville et al.	526	290	
BC	37	5,705,524	01/06/98	McGee et al.	514	431	
BC	38	5,723,458	03/03/98	Brieady et al.	514	211	
BC	39	5,767,115	06/16/98	Rosenblum et al.	514	210	
BC	40	5,929,062	07/27/99	Haines	514	182	



RECEIVED

OCT 29 2001

TECH CENTER 1600/2900
Serial No. 09/912,233


USPTO Form 1449 (modified) Patent and Trademark Office INFORMATION DISCLOSURE CITATION	U.S. Department of Commerce	Attorney Docket No. 061765.00035 (3356/US)	Applicant(s): TREMONT et al.	Examiner: Unassigned Group: 16147 1624
Page 2 of 9		Filing Date: July 25, 2001		

BC	41	5,994,391	11/30/99	Lee et al.	314	431	
BC	42	6,020,330	02/01/00	Enhnen et al.	314	211	
BC	43	6,034,118	03/07/00	Bischofberger et al.	314	431	

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Class	Subclass	Translation	
							YES	NO
BC	44	AU-A-30209/92	12/17/92	Australia				X
BC	45	AU-A-61946/94	06/05/94	Australia				X
BC	46	AU-A-61948/94	06/05/94	Australia				X
BC	47	AU-A-61949/94	06/05/94	Australia				X
BC	48	2,025,294	03/15/91	Canada				
BC	49	2,078,588	03/22/93	Canada				
BC	50	2,085,782	06/21/93	Canada				
BC	51	2,085,830	06/21/93	Canada				
** BC	52	0 067 086	10/05/82	Europe				
** BC	53	0 129 748	02/01/85	Europe				
BC	54	0 250 265	06/19/87	Europe				
** BC	55	0 338 331	06/04/89	Europe				
** BC	56	0 379 161	01/17/90	Europe				
BC	57	0 508 425 A1	09/04/92	Europe				
BC	58	0 526 402 A1	02/03/93	Europe				
BC	59	0 531 901 A2	02/09/92	Europe				
** BC	60	0 549 967 A1	12/17/92	Europe				
BC	61	0 559 064 A2	02/24/93	Europe				
** BC	62	0 563 731 A1	03/22/93	Europe				
** BC	63	0 568 898 A1	04/27/93	Europe				
** BC	64	0 796 846 A1	07/03/97	Europe				X
BC	65	0 801 060 A1	15/10/97	Europe				
** BC	66	0 818 197 A1	06/25/97	Europe				X
** BC	67	0 818 448 A1	06/24/97	Europe				X
** BC	68	2 661 676-A1	02/05/90	France				
** BC	69	196 27 430 A1	08/07/96	Germany				X
BC	70	1211258	02/01/68	Germany				
** BC	71	10-287662	10/27/98	Japan				X
BC	72	89/01477	02/23/89	PCT			Abst	
BC	73	91/08205	06/13/91	PCT			Abst	
BC	74	92/17467	10/15/92	PCT			Abst	
BC	75	92/18115	10/29/92	PCT			Abst	
BC	76	92/18462	10/29/92	PCT			Abst	
BC	77	93/16055	08/19/93	PCT			Abst	
BC	78	93/21146	10/28/93	PCT			Abst	
BC	79	94/18183	08/18/94	PCT			Abst	

** Structures only




RECEIVED
OCT 29 2001
TECH CENTER 1600/2900

USPTO Form 1449 (modified) Patent and Trademark Office INFORMATION DISCLOSURE CITATION				Attorney Docket No. 061765.00035 (3356/US)		Serial No. 09/912,233	
Page 3 of 9				Applicant(s): TREMONT et al.			
				Filing Date: July 25, 2001		Examiner: Unassigned Group: 16147 1624	
BC	80	94/18184	08/18/94	PCT		Abst	
** BC	81	94/24087	10/27/94	PCT		Abst	
BC	82	95/21843	08/17/95	PCT		Abst	
BC	83	96/05188	02/22/96	PCT		Abst	
BC	84	96/08484	03/21/96	PCT		Abst	
BC	85	96/16051	05/30/96	PCT		Abst	
BC	86	96/40255	12/19/96	PCT		Abst	
** BC	87	97/03953	02/02/97	PCT		Abst	
BC	88	97/33882	09/18/97	PCT		Abst	
BC	89	97/49387	12/31/97	PCT		Abst	
BC	90	97/49736	12/31/97	PCT		Abst	
BC	91	98/02432	01/22/98	PCT		Abst	
BC	92	98/06405	02/19/98	PCT		Abst	
BC	93	98/23593	06/04/98	PCT		Abst	
** BC	94	98/35937	08/20/98	PCT		Abst	
BC	95	98/38182	09/03/98	PCT		Abst	
BC	96	98/39299	09/11/98	PCT		Abst	
BC	97	98/40375	09/17/98	PCT		Abst	
BC	98	98/56757	12/17/98	PCT		Abst	
BC	99	99/11259	03/11/99	PCT			
BC	100	99/11260	03/11/99	PCT			
BC	101	99/11263	03/11/99	PCT			
** BC	102	99/14174	03/25/99	PCT		Abst	
BC	103	99/14204	03/25/99	PCT			
** BC	104	99/14215	03/25/99	PCT		Abst	
BC	105	99/32478	07/01/99	PCT			
BC	106	99/35135	07/15/99	PCT			
** BC	107	99/64409	12/16/99	PCT		Abst	
** BC	108	00/35889	06/22/00	PCT		Abst	
BC	109	2 305 665	04/16/97	United Kingdom			
BC	110	2 329 334	03/24/99	United Kingdom			
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)							
BC	111	A. Barrett et al., "Total Synthesis and Stereochemical Assignment of the Quinquecyclopropane-Containing Cholesteryl Ester Transfer Protein Inhibitor U-106305", J. Am Chem. Soc., 1996, 118, pgs. 7863-7864					
BC	112	P. Barter et al. "High Density Lipoproteins and Coronary Heart Disease", Atherosclerosis, 121 1996, pgs. 1-12.					
BC	113	A. Beckwith et al., "Iododediazoniation of Arenediazonium Salts Accompanied by Aryl Radical Ring Closure" J. Org. Chem. 1987, Vol. 52, pgs. 1922-1930					
BC	114	D. Bilheimer et al., "Mevinolin and Colestipol Stimulate Receptor-Mediated Clearance of Low					

** structures nly

OCT 29 2001

TECH CENTER 1600/2900

USPTO Form 1449 (modified) Patent and Trademark Office		U.S. Department of Commerce		Attorney Docket No. 061765.00035 (3356/US)		Serial No. 09/912,233	
INFORMATION DISCLOSURE CITATION Page 4 of 9							
				Filing Date: July 25, 2001			
		Density Lipoprotein From Plasma In Familial Hypercholesterolemia Heterozygotes", Proc. Natl. Acad. Sci. USA, Vol. 80, July 1983, pgs. 4124-4128					
BC	115	C. Bisgaier et al., "Cholesteryl Ester Transfer Protein Inhibition By PD 140195, Lipids, Vol. 29, No. 12, 1994, pgs. 811-818					
BC	116	D. Blankenhorn et al., "Beneficial Effects of Combined Colestipol-Niacin Therapy On Coronary Atherosclerosis and Coronary Venous Bypass Grafts", JAMA, June 19, 1987, Vol. 257, No. 23, pgs. 3233-3240					
BC	117	D. Blankenhorn et al., "Beneficial Effects of Colestipol-Niacin Therapy on the Common Carotid Artery" Circulation Vol. 88, 1 July 1993, pgs: 20-28					
BC	118	P. Bonin et al., "A Peptide Inhibitor Of Cholesteryl Ester Transfer Protein Identified By Screening a Bacteriophage Display Library", Journal of Peptide Research, 51, 1998, pgs. 216-225					
BC	119	G. Brown, et al., "Regression of Coronary Artery Disease As A Result of Intensive Lipid-Lowering Therapy in Men With High Levels Of Apolipoprotein B", The New England Journal of Medicine, Volume 323, November 8, 1990, Number 19, pgs. 1289-1339.					
BC	120	M. Brown et al., "Induction of 3-hydroxy-3Methylglutaryl Coenzyme A Reductase Activity in Human Fibroblasts Incubated with Compactin (ML-236B), A Competitive Inhibitor of the Reductase, The Journal of Biological Chemistry, Vol. 253, No. 4, February 22, 1978, pgs. 1121-1128					
BC	121	S. Busch et al., "Cholesteryl Ester Analogs Inhibit Cholesteryl Ester But Not Triglyceride Transfer Catalyzed By The Plasma Cholesteryl Ester-Triglyceride Transfer Protein", Lipids, Vol. 25, No. 4 (1990), pgs. 216-220					
BC	122	C. Camoutsis et al., "N-Substituted 4, 5-Dihydro-1, 2-Benzothiazepin-3-One 1, 1-Dioxide", J. Heterocyclic Chem. 17, pgs.1135-1136 (1980)					
BC	123	L. Cashin-Hemphill et al., "Beneficial Effects of Colestipol-Niacin on Coronary Atherosclerosis A 4-Year Follow-up", JAMA, December 19, 1990, Vol. 264, No. 23, pgs. 3013-3017					
BC	124	P. Catsoulacos et al., "Synthesis of Some N-Substituted 4,5-Dihydro-7,8-dimethoxybenzothiazepin-3-one 1,1-Dioxides", J. Heterocyclic Chem., Vol. 13 (1976), pgs. 1309-1314					
BC	125	P. Catsoulacos et al., "Thiazo Compounds. Derivatives of 4, 5-Dihydro-7, 8-Dimethoxybenzothiazepin-3 one 1, 1-Dioxides", Journal of Chemical and Engineering Data, Vol. 22, No. 3, 1977, pgs. 353-354					
BC	126	K. Cho et al, "A Peptide From Hog Plasma that Inhibits Human Cholesteryl Ester Transfer Protein", Biochimica et Biophysica Acta, 1391, 1998, pgs. 133-144					
BC	127	D. Connolly et al., "Inactivation of Cholesteryl Ester Transfer Protein by Cysteine Modification", Biochemical and Biophysical Research Communications 223, pgs. 42-47, 1996					
BC	128	S. Coval et al., "Wiedendiol-A and-B, Cholesteryl Ester Transfer Protein Inhibitors From The Marine Sponge Xestospongia Wiedenmayeri", Bioorganic & Medicinal Chemistry Letter, Vol. 5, No. 6, pgs. 605-610, 1995					
BC	129	J. Davignon et al., "Apolipoprotein E and Atherosclerosis: Quest for an APO E Receptor Defect Leads to the Discovery of Pseudo Type III Dyslipoproteinemia in a Family", Atherosclerosis IX, pgs. 199-203, 1992					
BC	130	J. Davignon et al., "Comparative Efficacy and Safety of Pravastatin, Nicotinic Acid and The Two Combined in Patients with Hypercholesterolemia", The American Journal of Cardiology, February 15, 1994, pgs. 339-345					

RECEIVED

OCT 29 2001

TECH CENTER 1600/2900

USPTO Form 1449 (modified) Patent and Trademark Office		U.S. Department of Commerce OCT 25 2001 PATENT & TRADEMARK OFFICE		Attorney Docket No. 061765.00035 (3356/US)	Serial No. 09/912,233
INFORMATION DISCLOSURE CITATION					
Page 5 of 9					
		Applicant(s): TREMONT et al.		Examiner: Unassigned Group: 16147 1624	
		Filing Date: July 25, 2001			
BC	131	C. East et al., "Combination Drug Therapy for Familial Combined Hyperlipidemia", Annals of Internal Medicine, July 1, 1988, pgs. 25-32			
BC	132	J. Emmerich et al., "Efficacy and Safety of Simvastatin (Alone or in Association with Cholestyramine) A 1 yr. Study in 66 Patients with Type II Hyperlipoproteinaemia", European Heart Journal (1990), 11, pgs. 149-155			
BC	133	D. Erkelens, "Combination Drug Therapy with HMG Co A Reductase Inhibitors and Bile Acid Sequestrants for Hypercholesterolemia", Cardiology, 1990, 77, (suppl 4). pgs. 33-38			
BC	134	H. Ginsberg, "Update on the Treatment of Hypercholesterolemia, with a Focus on HMG-CoA Reductase Inhibitors and Combination Regimens", Clinical Cardiology 18, pgs. 307-315, (1995)			
BC	135	C. Glueck et al., "Gemfibrozil-Lovastatin Therapy for Primary Hyperlipoproteinemias" The American Journal of Cardiology, July 1, 1992, Vol. 70, No. 1, pgs. 1-9			
BC	136	S. Grundy et al., "Influence of Combined Therapy with Mevinolin and Interruption of Bile-Acid Reabsorption on Low Density Lipoproteins in Heterozygous Familial Hypercholesterolemia", Annals of Internal Medicine, 1985, 103: pgs. 339-343			
BC	137	H. Gylling et al., "Effects Of Inhibiting Cholesterol Absorption And Synthesis On Cholesterol And Lipoprotein Metabolism In Hypercholesterolemic Non-Insulin-Dependent Diabetic Men", Journal of Lipid Research, Volume 37, 1996, pgs. 1776-1785			
BC	138	E. Haber, "Molecular Cardiovascular Medicine" Scientific American, pgs. 35-40			
BC	139	V. Hegde et al., "A Dipeptide Fungal Metabolite Inhibitor Of Cholesteryl Ester Transfer Protein", Bioorganic & Medicinal Chemistry Letters 8, 1998, pgs. 1277-1280			
BC	140	L. Hellberg et al., "5a-Hydroxy-3a-Cholestanecarboxylic" The New Journal for Organic Synthesis", Vol. 15, Number 1-2, February-April 1983, pgs. 154-156			
BC	141	J. Heubi et al., "Primary Bile Acid Malabsorption: Defective In Vitro Ileal Active Bile Acid Transport", Gastroenterology 1982, 83: pgs. 804-11			
BC	142	N. Hoogerbrugge et al., "The Additional Effects of Acipimox To Simvastatin In The Treatment of Combined Hyperlipidaemia", Journal of Internal Medicine, 1997, 241: pgs. 151-155			
BC	143	N. Hoogerbrugge et al., "The Efficacy and Safety of Pravastatin, Compared To And In Combination With Bile Acid Binding Resins, In Familial Hypercholesterolaemia", Journal of Internal Medicine 1990, 228; pgs. 261-266			
BC	144	A. Hutchesson et al., "Dual Bezafibrate-Simvastatin Therapy For Combined Hyperlipidaemia", Journal of Clinical Pharmacy and Therapeutics 1994, 19, pgs. 387-389			
BC	145	T. Ichihashi, "Mechanism of Hypocholesterolemic Action of S-8921 in Rats: S-8921 Inhibits Ileal Bile Acid Absorption", The Journal Of Pharmacology And Experimental Therapeutics, Vol. 284, No. 1, pgs. 43-50, 1998.			
BC	146	D. Illingworth, et al., "Influence of Lovstatin plus Gemfibrozil on Plasma Lipids and Lipoproteins in Patients With Heterozygous Familial Hypercholesterolemia", Circulation Vol. 79, Number 3, March 1989, 590-596			
BC	147	D. Illingworth, "Mevinolin Plus Colestipol in Therapy for Severe Heterozygous Familial Hypercholesterolemia", Annals of Internal Medicine, 1984; 101, pgs. 598-604			
BC	148	International Search Report mailed May 23, 2000 based on PCT/US 99/27942			
BC	149	International Search Report mailed May 23, 2000 based on PCT/US 99/27943			
BC	150	International Search Report mailed May 23, 2000 based on PCT/US 99/27944			
BC	151	International Search Report mailed May 23, 2000 based on PCT/US 99/27945			
BC	152	International Search Report mailed May 18, 2000 based on PCT/US 99/27947			

OCT 29 2001


TECH CENTER 1600/2900

USPTO Form 1449 (modified) Patent and Trademark Office INFORMATION DISCLOSURE CITATION		U.S. Department of Commerce Patent & Trademark Office OCT 25 2001		Attorney Docket No. 061765.00035 (3356/US)	Serial No. 09/912,233
Page 6 of 9		Applicant(s): TREMONT et al.			Examiner: Unassigned Group: 16147-1624
		Filing Date: July 25, 2001			
BC	153	International Search Report mailed May 15, 2000 based on PCT/US 99/27948			
BC	154	International Search Report mailed May 17, 2000 based on PCT/US 99/27949			
BC	155	J. Kane, et al., "Regression of Coronary Atherosclerosis During Treatment of Familial Hypercholesterolemia With Combined Drug Regimens", JAMA, December 19, 1990, Chapter 26, Vol. 264, No. 23, pgs. 3007-3012			
BC	156	A. Katritzky et al., "Preparation Of 6-7- And 8-Membered Sultams By Friedel-Crafts Cyclization Of w-Phenylalkanesulfamoyl Chlorides", Organic Preparations and Procedures Int., 24 (4), pgs. 463-467 (1992)			
BC	157	T. Kazumi et al., "Effects of Niceritrol On Elevated Serum Lipoprotein LP (A) Levels in Diabetic Patients With Or Without Overt Proteinuria", Current Therapeutic Research, Vol. 55, No. 5, May 1994, pgs. 546-551			
BC	158	W. Kramer, et al., "Intestinal Bile Acid Absorption", The Journal of Biological Chemistry". Vol. 268, No. 24 Issue of August 25, pgs. 18035-18046, 1993			
BC	159	Kuo, M.S. et al., "Discovery, Isolation, Structure Elucidation, and Biosynthesis of U-106305, a Cholesteryl Ester Transfer Protein Inhibitor from UC 11136", J. Am. Chem. Soc. 117, pp. 10629-10634 (1995)			
BC	160	Kvis, K. et al., "Benzocycloheptenes and Heterocyclic Analogues as Potential Drugs. VII, 4-Phenyl-,3,4,5-Tetrahydro-1-Benzothiepins and Some Related Compounds", Chem. Commun./Vo.37/(1973) pgs. 3808-3816			
BC	161	Lee, J.C. et al., "A Cholesteryl Ester Transfer Protein Inhibitor from an Insect-associated Fungus", The Journal of Antibiotics 49(7), pp. 693-696, 1996.			
BC	162	A.M. Lees et al., "Therapy of Hypercholesterolemia With Mevinolin And Other Lipid-Lowering Drugs", Arteriosclerosis 6, 1986, pg. 544a			
BC	163	T. Leren et al., "Effects of Lovastatin Alone and In Combination with Cholestyramine on Serum Lipids and Apolipoproteins in Heterozygotes for Familial Hypercholesterolemia", International Journal for Research and Investigation on Atherosclerosis and Related Diseases, 73, (1988), pgs. 135-141			
BC	164	M. Lewis, et al., "Effects Of 2164U90 on Ileal Bile Acid Absorption and Serum Cholesterol in Rats and Mice, Journal of Lipid Research, Vol. 36, 1995, pgs. 1098-1105			
BC	165	R. Lewis, Hawley's Condensed Chemical Dictionary, pg. 1238			
BC	166	W. Ling et al., "Minireview Dietary Phytosterols A Review of Metabolism, Benefits and Side Effects", Life Sciences, Vol. 57, No. 3, 1995, pgs. 195-206			
BC	167	H. Mabuchi et al., "Reduction of Serum Cholesterol In Heterozygous Patients with Familial Hypercholesterolemia", The New England Journal of Medicine, Vol. 308, March 17, 1983, pgs. 609-613			
BC	168	M. Malloy et al., "Complementarity of Colestipol, Niacin, and Lovastatin in Treatment of Severe Familial Hypercholesterolemia", Annals of Internal Medicine 1987; 107: pgs. 616-623			
BC	169	W. Mandeville et al., "Bile Acid Sequestrants: Their Use In Combination With Other Lipid-Lowering Agents, Idrugs 1999 Vol. 2., No. 3, pgs. 237-242			
BC	170	G. Marais et al., "Rhabdomyolysis and Acute Renal Failure Induced by Combination Lovastatin and Gemfibrozil Therapy", Annals of Internal Medicine, February 1, 1990, Volume 112, Number 3, pgs. 228-230			
BC	171	P. McCarthy, "New Approaches to Atherosclerosis: An Overview", Medicinal Research Reviews, Vol 13 No 2 1993 pgs 139-159			

RECEIVED

OCT 29 2001

TECH CENTER 1600/2900

USPTO Form 1449 (modified) Patent and Trademark Office		U.S. Department of Commerce		Attorney Docket No. 061765.00035 (3356/US)		Serial No. 09/912,233	
INFORMATION DISCLOSURE CITATION Page 7 of 9							
				Filing Date: July 25, 2001			
		Vol. 13, 1993, pgs. 139-159					
BC	172	R. Morton, "Regulation of Lipid Transfer Between Lipoproteins By An Endogenous Plasma Protein: Selective Inhibition Among Lipoprotein Classes, Journal of Lipid Research, Vol. 35, 1994, pgs. 836-847					
**BC	173	F. Nerdel et al., "Quartermay Salts of B-Amino Aldehydes and B-Iodoaldehydes", Chemische Berichte (Ed. H. Zahn), Vol. 98 (1965), pgs. 728-734					
BC	174	M. Newman et al., "The Conversion of Phenols to Thiophenols via Dialkylthiocarbamates", The Journal Of Organic Chemistry, Vol. 31, September-December 1966, pgs. 3980-3984					
BC	175	A. Orahovats et al., "A Ring Enlargement from Seven-to Ten-Membered-Ring Sulfonamide Derivatives", Helvetica Chimica Acta, Vol. 79, (1996), pgs. 1121-1128					
BC	176	H. Pan et al., "Pharmacokinetics and Pharmacodynamics of Pravastatin Alone and With Cholestyramine in Hypercholesterolemia", Clin. Pharmacol Ther. (1980) 9, 313, pgs. 201-207					
BC	177	N. Panagiotopoulos et al., "N(P-Bromophenyl) -4,5 - Dihydro -7, 8 - Dimethoxy Benzothiazepine - ONE 1, 1-Dioxide C17 H16 brNO5S", Cryst. Struct. Comm. (1980) 9, pgs. 313-319					
BC	178	R. Pasternak et al., "Effect of Combination Therapy with Lipid-Reducing Drugs in Patients with Coronary Heart Disease and "Normal" Cholesterol Levels", Annals of Internal Medicine, October 1, 1996, Vol. 125, Number 7, pgs. 529-538					
BC	179	R. Patra et al., "Conformational and Steric Requirements Of The Side Chain For Sulphur Participation In Benzthiepin Derivatives", Tetrahedron Letters, Vol. 30, No. 32, pgs. 4279-4282, 1989					
BC	180	R. Pierce et al., "Myopathy and Rhabdomyolysis Associated With Lovastatin-Gemfibrozil Combination Therapy, JAMA, July 4, 1990, Vol. 264, No. 1, pgs. 71-75					
BC	181	W. Pirkle et al., "Trichlorosilane-Induced Cleavage. A Mild Method for Retrieving Carbinols From Carbamates", Jouranal Organic Chemistry, Vol. 42, No. 15, 1977, pgs. 2781-2782					
BC	182	W. Pirkle et al., "Dynamic NMR Studies of Disatereomeric Carbamates: Implications toward the Determination of Relative Configuration by NMR" Journal of Organic Chemistry, Vol. 44, No. 26, 1979, pgs. 4891-4896					
BC	183	W. Pirkle et al., "An Example of Automated Liquid Chromatography Synthesis of a Broad-Spectrum Resolving Agent and Resolution of 1-(Naphthyl) 2, 2, 2-Trifluoroethanol", The Journal of Organic Chemistry Volume 39, No. 26, 1974, pgs. 3904-3906					
BC	184	T. Pietzonka et al., "Phosphonate-Containing Analogs Of Cholesteryl Ester As Novel Inhibitors Of Cholesteryl Ester Transfer Protein", Bioorganic & Medicinal Chemistry Letters, Vol. 6, No. 16, pgs. 1951-1954, 1996.					
BC	185	Pravastatin Multicenter Study Group II, "Comparative Efficacy and Safety of Pravastatin and Cholestyramine Alone And Combined in Patients With Hypercholesterolemia", Archives of Internal Medicine, Vol. 153, June 14, 1993, pgs. 1321-1328					
BC	186	E. Reihner et al., "Regulation of Hepatic Cholesterol Metabolism In Humans: Stimulatory Effects of Cholestyramine on HMG-CoA Reductase Activity and Low Density Lipoprotein Receptor Expression In Gallstone Patients, Journal of Lipid Research, Volume 31, 1990, pgs. 2219-2226					
BC	187	R. Remick et al., "Comparison of Fluoxetine and Desipramine In Depressed Outpatients", Therapeutic Research, Vol. 53, No. 5, May 1993, pgs. 457-483					
BC	188	S. Rosenblum et al., "Discovery of 1-(4-Fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally					

** structures only

RECEIVED

OCT 29 2001


USPTO Form 1449 (modified) Patent and Trademark Office INFORMATION DISCLOSURE CITATION Page 8 of 9		U.S. Department of Commerce OCT 25 2001 PATENT & TRADEMARK OFFICE		Attorney Docket No. 061765.00035 (3356/US)	TECH CENTER 1600/2900 09/912,233
Applicant(s): TREMONT et al.				Examiner: Unassigned Group: 16147 1624	
Filing Date: July 25, 2001					
		Active Inhibitor of Cholesterol Absorption, Journal of Medicinal Chemistry, 1998, Vol. 41, No. 6, pgs. 973-980			
BC	189	G. Salem et al., "Benzothiazine and Benzothiazepine Derivatives: Structures of N-p-Bromophenyl-6, 7-Dimethoxy-1, 2-Benzothiazin-3(4H)-One 1, 1-Dioxide (BBTZ) and 4, 5-Dihydro-8,9-Dimethoxy-N-(5-Methyl-2-Pyridyl)-1,2-Benzothiazepin-3-One 1, 1-Dioxide (MPTE)", Acta Cryst. (1986) C42, pgs. 1581-1584			
BC	190	J. Sasaki et al., "Effects of Fluvastatin, A New Inhibitor of HMG-CoA Reductase, and Niceritol on Serum Lipids, Lipoproteins and Cholesterol Ester Transfer Activity In Primary Hypercholesterolemic Patients", International Journal of Clinical Pharmacology and Therapeutics, Vol. 33, No. 7, 1995, pgs. 420-426			
BC	191	K. Sindelar et al., "Neurotropic and Psychotropic Compounds. XXIX. Derivatives Of 2,3,4,5-Tetrahydro-1-Benzothiepin, Chemical Commun., Vol. 33, 1968, pgs. 4315-4327			
BC	192	K. Sindelar et al., "Benzocycloheptenes and Heterocyclic Analogues As Potential Drugs. III. Further Synthetic Experiments In The Series Of 1-Benzothiepin Derivatives, Vol. 37, 1972, 1195-1206			
BC	193	C. Sirtori, "New Targets For Lipid Lowering And Atherosclerosis Prevention", Pharmac. Ther. Vol. 67, No. 3., pgs. 433-447, 1995			
BC	194	Y. Son, "Purification and Characterization of Human Plasma Proteins That Inhibit Lipid Transfer Activities", Biochimica et Biophysica Acta, 795, 1984, pgs. 473-480			
BC	195	D. Sprecher et al., "Low-Dose Combined Therapy with Fluvastatin and Cholestyramine in Hyperlipidemic Patients", Ann Intern Med. 1994; 120: pgs. 537-543			
BC	196	C.I. Stassinopoulou, et al., "C NMR Spectra of Benzothiazepinone, Benzothiazinone and Benzosulphonamide N-Substituted Derivatives" Department of Biology, Nuclear Research Center, 1982.			
BC	197	E. Stedronsky et al., "Interaction of Bile Acids and Cholesterol with Non-Systemic Agents Having Hypocholesterolemic Properties", Biochimica et Biophysica Acta., 1210, 1994, pgs. 255-287			
BC	198	I. Stein, et al., "Effects of Simvastatin and Cholestyramine in Familial and Nonfamilial Hypercholesterolemia", Arch Intern Med. Vol. 150, February 1990, pgs. 341-345			
BC	199	E. Stein, et al., "Lovastatin Alone And In Combination For Treatment Of Primary Hypercholesterolemia", Alan R. Liss, Inc. 1988, pgs. 281-293			
BC	200	K. Suckling, et al., "Cholesterol Lowering and Bile Acid Excretion in the Hamster with Cholestyramine Treatment, Atherosclerosis, 89, (1991) pgs. 183-190			
BC	201	T. Swenson, "Mechanism of Cholesteryl Ester Transfer Protein Inhibition by a Neutralizing Monoclonal Antibody and Mapping of the Monoclonal Antibody Epitope", The Journal of Biological Chemistry, Vol. 264, No. 24, Aug. 25, pgs. 14318-14326, 1989			
BC	202	A. Tall, "Plasma Cholesteryl Ester Transfer Protein", Journal of Lipid Research", Volume 34, 1993, pgs. 1255-1274			
BC	203	Y. Tamura et al., "Novel Conversions of Benzo [b] thiophen-3 (2-H)-ones into 1, 2-Benzisothiazole and Tetrahydro-1, 2-Benzothiazepin-5-One Systems via Sulphimide Intermediates, J.C.S. Perkin I, pgs. 2830-2834, 1980			
BC	204	K. Thurmond et al., "Water-Soluble Knedel-like Structures: The Preparation of Shell-Cross-Linked Small Particles", Journal American Chemistry Soc. Vol., 118, No. 30, 1996, pgs. 7239-7240			
BC	205	P. Tyle, "Iontophoretic Devices for Drug Delivery", Pharmaceutical Research, Vol. 3. No. 6 1986, pgs. 318-325			

RECEIVED

OCT 29 2001

USPTO Form 1449 (modified) Patent and Trademark Office		U.S. Department of Commerce		Attorney Docket No. 061765.00035 (3356/US)		TECH CENTER 1600/2900 09/912,233	
INFORMATION DISCLOSURE CITATION Page 9 of 9				Applicant(s): TREMONT et al.			
				Filing Date: July 25, 2001		Examiner: Unassigned Group: 16147 1624	
BC	206	M. Une et al., "Metabolism of 3a, 7a-Dihydroxy-7b-Methyl-5b-Cholanoic Acid and 3a, 7B-Dihydroxy-7a-Methyl-5B-Cholanoic Acid Hamsters, Biochimica et Biophysica Acta, 833 (1985), pgs. 196-202					
BC	207	J. Vacek et al., "Comparison of Lavastatin (20 mg) and Nicotinic Acid (1.2g) With Either Drug Alone for Type II Hyperlipoproteinemia, The American Journal Of Cardiology, Vol. 76, July 15, 1995, pgs. 182-184					
BC	208	M. Van Heek et al., "In Vivo Metabolism-Based Discovery of a Potent Cholesterol Absorption Inhibitor, SCH58235, in the Rat and Rhesus Monkey Through the Identification of the Active Metabolites of SCH48461", The Journal of Pharmacology and Experimental Therapeutics, Vol. 283, No. 1, pgs. 157-754, 1997.					
BC	209	G. Vega et al., "Treatment of Primary Moderate Hypercholesterolemia With Lovastatin (Mevinolin) and Colestipol", JAMA, Jan 2, 1987, Vol. 257, No. 1, pgs. 33-37					
BC	210	G. Wess et al., "Synthesis and Biological Activity of Bile Acid-Derived HMG-CoA Reductase Inhibitors. The Role of 21-Methyl in Recognition of HMG-CoA Reductase and the Ileal Bile Acid Transport System", Journal Of Medicinal Chemistry" 1994, 37, pgs. 3240-3246					
BC	211	J. Wetterau et al., "An MTP Inhibitor that Normalizes Atherogenic Lipoprotein Levels In WHHL Rabbits", Science Vol. 282, 10/23/98, pgs. 751-754					
BC	212	O. Wiklund et al., "Pravastatin and Gemfibrozil Alone and in Combination for the Treatment of Hypercholesterolemia", The American Journal of Medicine Vol. 94, January 1993, pgs. 13-19					
BC	213	S. Wirebaugh et al., "A Retrospective Review of the Use of Lipid-Lowering Agents in Combination, Specifically, Gemfibrozil and Lovastatin", Pharmacotherapy Vol. 12, Number 6, 1992, pgs. 445-450					
BC	214	J. Witztum, "Drugs Used In The Treatment of Hyperlipoproteinemias", The Pharmacological Basis of Therapeutics, 9 th Edition, pgs. 875-894, 1996.					
BC	215	Yan Xia et al., "Substituted 1,3,5-Triazines As Cholesterol Ester Transfer Protein Inhibitors", Bioorganic & Medicinal Chemistry Letters, Vol. 6, No. 7, 1996, pgs. 919-922					
BC	216	A. Yamamoto et al., "Effects of Probucol on Xanthomata Regression in Familial Hypercholesterolemia", Am Journal Cardiolgy, 1986, 57: pgs. 29H-35H					
BC	217	K. Ytre-Arne et al., "Simvastatin and Cholestyramine In The Long-Term Treatment of Hypercholesterolaemia", Journal of Internal Medicine (1989): 226, pgs. 285-90					
EXAMINER <i>Brenda Coleman</i>				DATE CONSIDERED <i>June 13, 2003</i>			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant. **Copies of references not provided at the time of this submission.							

Please type a plus sign (+) inside this box



Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

#5

PTO/SB/08A (08-00)

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	09/912,233
Filing Date	July 25, 2001
First Named Inventor	TREMONT et al.
Group Art Unit	4014 1624
Examiner Name	Unassigned
Attorney Docket Number	061765.00195 (S0-3356/01/US)

RECEIVED
JUN 25 2002
CENTER 1601290

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number	Kind Code ² (if known)			class	subclass
BC	218.	3,694,446		Houlihan et al.	09/26/72	260	268 BC
	219.	4,946,227		Terahara et al.	08/24/82	duplicate	
BC	220.	4,410,629		Terahara et al.	10/18/83	435	146
BC	221.	4,448,979		Terahara et al.	05/15/84	549	292

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
** BC	222.	DE	3 122 499	A1	Germany	12-24-1981		
BC	223.	EP	0 022 487	A1	Europe	01-21-1981		
BC	224.	EP	0 033 538	B1	Europe	08-12-1981		
BC	225.	EP	0 244 364	A2	Europe	11-04-1987		
BC	226.	EP	0 409 281	A1	Europe	01-23-1991		
BC	227.	GB	1 211 258		Great Britain	11-04-1970		
BC	228.	GB	2 077 264	A'	Great Britain	12-16-1981		
	229.	WO	98/38182				duplicate	
	230.	WO	98/40975				duplicate	
** BC	231.	WO	00/61568	A	PCT	10-19-2000		

Examiner Signature	Branda Coleman	Date Considered	June 13, 2003
--------------------	----------------	-----------------	---------------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

** structures only

Please type a plus sign (+) inside this box →



PTO/SB/081 (08-00)

Approved for use through 10/31/2002. OMB 0834-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	09/912,233
Filing Date	July 25, 2001
First Named Inventor	TREMONT et al.
Group Art Unit	4644 1624
Examiner Name	Unassigned
Attorney Docket Number	061765.00195 (S0-3356/01/US)

TECHNICAL CENTER 1600/2900

JUN 25 2002

RECEIVED

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Be	232.	Angelin, B., "Regulation of Hepatic Cholesterol Metabolism in Man," Ann. Med. 23, pp. 10-27 (1991).	
Be	233.	Blum, C. B., "Comparison of Properties of Four Inhibitors of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase," Am. J. Cardiol., 73(14), 3D-11D, (1994).	
Be	234.	Cayen, M.N., "Disposition, Metabolism and Pharmacokinetics of Antihyperlipidemic Agents in Laboratory Animals and Man," Pharmac. & Ther., 29, pp. 157-204 (1985).	
Be	235.	Da Col, et al., "Tolerability and Efficacy of Combination Therapy with Simvastatin Plus Gemfibrozil in Type II Refractory Familial Combined Hyperlipidemia," Curr. Therap. Research, Vol. 53, No. 5, pp. 473-483 (1993).	
Be	236.	Davignon, et al. "HMG CoA Reductase Inhibitors: A look back and a look ahead," Can. J. Cardiol., 8(8), pp. 843-864 (1992).	
Be	237.	Endo, A. "Chemistry, biochemistry and pharmacology of HMG-Co-A reductase inhibitors," Klin. Wochenschr. 66, pp. 421-427 (1988).	
Be	238.	Kramer et al., "Bile acid derived HMG-CoA reductase inhibitors," Biochimica et Biophysica Acta, 1227 pp. 137-154 (1994).	
Be	239.	Marcus, A., "Role of the HMG-CoA Reductase Inhibitors in the Treatment of Dyslipidemia: An Evolutionary Review," CVR&R, pp. 13-27 (January 1996).	

Examiner Signature	Brenda Coleman	Date Considered	June 13, 2003
--------------------	----------------	-----------------	---------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.